Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) (RIVAL)

NCT02092532 Phase 4 UNKNOWN

The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.

Details

Lead sponsor	Southeast Retina Center, Georgia
Phase	Phase 4
Status	UNKNOWN
Enrolment	20
Start date	2014-03
Completion	2016-03

Conditions

• Neovascular Polypoidal Choroidal Vasculopathy

Interventions

• Rescue Intravitreal Aflibercept Injection
• Rescue Therapy with PDT, Laser or Intravitreal Steroids

Primary outcomes

• Incidence and Severity — Month 6
  The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 6.
• Incidence and Severity — Month 12
  The primary objective of the study is the incidence and severity of ocular and systemic adverse events at Month 12.

Countries

United States